EAM
JUNO

EULAV Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

EULAV Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-135,000
Closed -$6.17M – 308
2017
Q4 		$6.17M Buy
+135,000
New +$6.73M 0.29% 118

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

EULAV Asset Management's JUNO Position: Q1 2018 in Review

EULAV Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 135,000 shares — an estimated $6.17M sold.

EULAV Asset Management first reported a position in JUNO in Q4 2017 and held it in 1 quarter. The position peaked at $6.17M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • EULAV Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • EULAV Asset Management sold 135,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $6.17M.
  • EULAV Asset Management first reported a position in Juno Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • EULAV Asset Management's Juno Therapeutics, Inc. position peaked at $6.17M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on EULAV Asset Management's 13F filing for Q1 2018, filed 9 May 2018.